CCR3 antagonists: A survey of the patent literature

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 8, 2009, Pages 1109-1132

  Gong, Leyi ^a   Wilhelm, Robert S ^b  

^a ROCHE BIOSCIENCE   (United States)

^b NONE

Author keywords

Airway inflammation; CCR3; CCR3 antagonists; CCR3 receptor; Eosinophil; Eotaxin

Indexed keywords

4 [3 [4 (3,4 DICHLOROBENZYL) 2 MORPHOLINYLMETHYL]UREIDOMETHYL]BENZAMIDE; AZETIDINE DERIVATIVE; BERTILIMUMAB; BMS 639623; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR3 ANTAGONIST; CYTOCHROME P450 REDUCTASE; DPC 168; IMIDAZOLE DERIVATIVE; MORPHOLINE; PIPERIDONE DERIVATIVE; POTASSIUM CHANNEL HERG; PYRROLIDINE DERIVATIVE; SB 297006; SB 328437; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BINDING AFFINITY; CALCIUM MOBILIZATION; CELL DIFFERENTIATION; CELL INFILTRATION; CHEMOTAXIS; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; EOSINOPHIL; EX VIVO STUDY; GUINEA PIG; HUMAN; IC 50; IN VITRO STUDY; LUNG FUNCTION; MAST CELL; MAST CELL DEGRANULATION; NONHUMAN; NOSE ALLERGY; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION; TH2 CELL;

ANIMALS; HUMANS; INTERLEUKIN-5; MORPHOLINES; PATENTS AS TOPIC; PIPERIDINES; PYRROLIDINES; RECEPTORS, CCR3;

EID: 68249124539     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903008544     Document Type: Review

References (128)

1. Kunkel SL, Standiford TJ, Strieter RM, Kasama T. Chemotactic cytokines: the chemokine family. Lung Biol Health Dis 1995;80:579-597
2. Lukacs NW, Hogaboam CM, Kunkel SL. Chemokines and their receptors in chronic pulmonary disease. Curr Drug Targets Inflamm Allergy 2005;4:313-317 (Pubitemid 40873117)
3. Coelho AL, Hogaboam CM, Kunkel SL. Chemokines provide the sustained inflammatory bridge between innate and acquired immunity. Cytokine Growth Factor Rev 2005;16:553-560
4. Kunkel SL, Godessart N, Hogaboam CM, et al. Chemokines in animal models of inflammation. Birkhaeuser Verlag: Chemokine Biology-Basic Research and Clinical Application 2007;2:3-17
5. Hudgson S, Charlton S, Warne P. Chemokines and drug discovery. Drug News Perspect 2004;17:335-338
6. D'Elios MM, Prete GD, Amedei A. Interfering with chemolines and chemokine receptors as potential new therapeutic strategies. Expert Opin Ther Patents 2008;18:309-325 (Pubitemid 351577863)
7. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:145-176
8. Graham GJ. D6 and the atypical chemokine receptor family: Novel regulators of immune and inflammatory processes. Eur J Immunol 2009;39:342-351
9. Jose PJ, Griffiths-Johnson DA, Collin PD, et al. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med 1994;179:881-887
10. Daugherty BL, Siciliano SJ, DeMartino JA, et al. Cloning, expression and characterization of the human eosinophil eotaxin receptor. J Respir Med 1996;183:2349-2354 (Pubitemid 26158926)
11. Uguccioni M, Mackay CR, Ochensberger B, et al. High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotazin, MCP-4 and other chemokines. J Clin Invest 1997;100:1137-1143 (Pubitemid 27386297)
12. Price KS, Friend DS, Mellor EA, et al. CC chemokine receptor 3 mobilizes to the surface of human mast cells and potentiates immunoglobulin E-dependent generation of interleukin 13. Am J Respir Cell Mol Biol 2003;2:420-427
13. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997;277:2005-2007 (Pubitemid 27449145)
14. Nakamura H, Weiss ST, Israel E, et al. Eotaxin and impaired lung function in asthma. Am J Respir Crit Care Med 1999;160:1952-1956 (Pubitemid 30004702)
15. De Lucca GV. Recent developments in CCR3 antagonists. Curr opin Drug Discov Dev 2006;9:516-524 • A very good review on CCR3 biology and chemistry up to 2006.
16. Humbles AA, Lu B, Friend DS, et al. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyper responsiveness. PNAS 2002;99:1479-1484 (Pubitemid 34136518)
17. Pope SM, Zimmermann N, Stringer KF, et al. The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. J Immunol 2005;175:5341-5350 (Pubitemid 41456420)
18. Ma W, Bryce PJ, Humble AA, et al. CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J Clin Invest 2002;109:621-628
19. Mattes J, Yang M, Mahalingam S, et al. Intrinsic defect in T cell production of interleukin (IL-13) in the absence of both IL-5 and eotaxin prcludes the development of eosinophilia and airways hyper reactivity in experimental asthma. J Exp Med 2002;195:1433-1444 (Pubitemid 34602820)
20. Dent G, Hadjicharalambous C, Yoshikawa R, et al. Contribution of eotaxin-1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum. Am J Respir Crit Care 2004;169:1110-1117 (Pubitemid 38624790)
21. Pereira S, Clark T, Darby Y, et al. Effects of anti-eotaxin monoclonal antibody CAT-213 on nasal allergen-induced rhinitis [abstract]. J Allergy Clin Immunol 2003;111:S268
22. Salib R, Salagean M, Lau L, et al. The anti-inflammatory response of anti-eotaxin monoclonal antibocy CAT-213 on nasal allergen-induced cell infiltration and activation [abstract]. J Allergy Clin Immunol 2003;111:S347
23. Nakamura H, Luster AD, Nakamura T, et al. Variant eotaxin: Its effects on the asthma phenotype. J Allergy Clin Immunol 2001;108:946-953 (Pubitemid 33151547)
24. Fuentes ME, Mirzadegan T, Wilhelm RS. Chapter 4. Chemokine and cytokine modulators in Burger's Medicinal chemistry & Drug Discovery, Sixth edition. John Wiley and Sons; 2003. p. 129-202
25. Naya A, Saeki T. Chemokine CCR3 antagonists. Expert Opin Ther Patents 2004;14:7-16 • A thorough patent literature review on CCR3 antagonists up to 2003.
26. Mori A, Ogawa K, Someya K, et al. Selective suppression of Th2-mediated airway eosinophil infiltration by low-molecular weight CCR3 antagonists. Int Immunol 2007;10:913-921
27. Schlyer S, Horuk R. I want a new drug: G-protein-coupled receptors in drug development. Drug Discov Today 2006;11:481-493
28. Kelly J, et al. US pharma: notes from the IRA conference-future drugs appearing on the horizon. Oct. 2002, Goldman Sachs
29. Das AM, Vaddi KG, Solomon KA, et al. Selective inhibition of eosinophil influx into the lung by small molecule CC chemokine receptor 3 antogonists in mouse models of allergic inflammation. J Pharm Exp Ther 2006;318:411-417
30. GlaxoSmithKline's CCR3 chemokine receptor antagonists. Expert Opin Ther Patents 2004;14:577-582 (Pubitemid 38489497)
31. Mirzadegan T, Diehl F, Ebi B, et al. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists. J Biol Chem 2000;275:25562-25571
32. AstraZeneca AB. Piperidine derivatives useful as modulators of chemokine receptor activity. WO2003004487; 2003
33. AstraZeneca AB. Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity. WO2003024962; 2003
34. AstraZeneca AB. Piperidine derivatives useful as modulators of chemokine receptor activity. WO2003078395; 2003
35. AstraZeneca AB. Novel piperidine derivatives for use in the treatment of chemokine mediated disease states. WO2004029041; 2004
36. AstraZeneca AB. Piperidine derivatives for the treatment of chemokine or h1 mediated disease state. WO2004085423; 2004
37. AstraZeneca AB. Chemical compounds. WO2004099144; 2004
38. AstraZeneca AB. Preparation of pharmaceutical salts of [1, 4]-bipiperidine. WO2005044268; 2005
39. AstraZeneca AB. Novel piperidines as chemokine modulators (ccr). WO2005073192; 2005
40. AstraZeneca AB. Piperidine derivates for the treatment of chemokines mediared disease. WO2005097775; 2005
41. AstraZeneca AB. Piperidines for the treatment of chemokine mediated diseases. WO2006126947; 2006
42. AstraZeneca AB. Piperidines for the treatment of chemokine mediated diseases. WO2006126948; 2006
43. AstraZeneca AB. Piperidine derivatives useful for treating osteoarthritis and osteoartrosis. WO2007114770; 2007
44. AstraZeneca AB. Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity. WO2008010765; 2008
45. Bristol-Myers Squibb Co. N-Ureidoalkyl-piperidines as modulators of chemokine receptor activity. WO2004110993; 2004
46. Bristol-Myers Squibb Co. N-Ureidoalkyl-amino compounds as modulators of chemokine receptor activity WO2005048932; 2005
47. Sabroe I, Hartnell AJ, Louise A, et al. Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways. J Immunol 1999;162:2946-2955 (Pubitemid 29309323)
48. Sabroe I, Peck MJ, Keulen BJV, et al. A small molecule antagonist of the chemokine receptors CCR1 and CCR3: potent inhibition of Eosinophil function and CCR3-mediated HIV-1 entry. J Biol Chem 2000;275:25985-25992 (Pubitemid 30676638)
49. Novartis AG. Azetidine derivatives as CCR-3 receptor antagonists. WO2003077907; 2003
50. Novartis AG. Piperidin-acetamide derivatives for the treatment of inflammatory or allergic diseases. WO2008092844; 2008
51. Bristol-Myers Squibb Co. Substituted piperidines as modulators of chemokine receptor activity. US2008081824; 2008
52. Bristol-Myers Squibb Co. Substituted spiro azabicyclics as modulators of chemokine receptor activity. WO2005080376; 2005
53. Wacker DA, Varnes JG, Gardner DS, et al. Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists. Bioorg Med Chem Lett 2004;14:1645-1649
54. De Lucca GV, Kim UT, Vargo BJ, et al. Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency. J Med Chem 2005;48:2194-2211 (Pubitemid 40396347)
55. Batt DG, Houghton GC, Roderick J, et al. N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists. Bioorg Med Chem Lett 2005;15:787-791 (Pubitemid 40143166)
56. Watson PS, Jiang B, Harrison K, et al. 2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity. Bioorg Med Chem Lett 2006;16:5695-5699
57. Pruitt JR, Batt DG, Wacker DA, et al. CC chemokine receptor-3 (CCR3) antagonists: Improving the selectivity of DPC168 by reducing central ring lipophilicity. Bioorg Med Chem Lett 2007;17:2992-2997
58. Duncia JV, Santella JB, Gardner DS, et al. From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis. Bioorg Med Chem Lett 2008;18:576-585
59. Duncia JV, Gardner DS, Santella JB III, et al. From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists. Bioorg Med Chem Lett 2008;18:586-595
60. Dhar TG, Yang G, Davis P, et al. Urea based CCR3 antagonists employing a tetrhydro-1,3-oxazin-2-one spacer. Bioorg Med Chem Lett 2009;19:96-99
61. Bristol-Myers Squibb Co. N-Ureidoalkyl-piperidines as modulators of chemokine receptor activity. WO2004024682; 2004
62. Boehringer Ingelheim Pharma GmbH & Co. Novel substituted piperidyl-propane-thiols. WO2008049875; 2008
63. Boehringer Ingelheim Pharma GmbH & Co. Piperidyl-propane-thiol CCR3 modulators. WO2008049874; 2008
64. Boehringer Ingelheim Pharma GmbH & Co. Novel Piperidine-substituted indoles. US2006247230; 2006
65. Boehringer Ingelheim Pharma GmbH & Co. Novel piperidine substituted indoles or heteroderivatives thereof. WO2005049559; 2005
66. Boehringer Ingelheim Pharma GmbH & Co. Alkyl- and piperidine-substituted benzimidazole-derivates. WO2006013073; 2006
67. Boehringer Ingelheim Pharma GmbH & Co. Haloalkyl- and piperidine-substituted benzimidazole-derivatives. WO2005019203; 2005
68. Boehringer Ingelheim Pharma GmbH & Co. N-(Heterobicycloalkanes)- substituted indoles or heteroderivatives thereof. WO2005005425; 2005
69. AstraZeneca AB. Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them. WO2007102767; 2007
70. AstraZeneca AB. Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them. WO2007102768; 2007
71. AstraZeneca AB. Chemical compounds III. WO2007102769; 2007
72. AstraZeneca AB. Novel piperidine derivatives. WO2007011293; 2007
73. Bryan SA, Jose PJ, Topping JR, et al. Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists. Am J Respir Crit Care Med 2002;165:1602-1609
74. Hoffmann-La Roche AG. Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists. US2005090504; 2005
75. Hoffmann-La Roche AG. Cyclic amine derivatives-CCR-3 receptor antagonists. US6339087; 2002
76. Hoffmann-La Roche AG. CCR-3 receptor antagonists. WO2004076448; 2004
77. Gong L, Hogg JH, Collier J, et al. Design and synthesis of novel CCR3 antagonists. Bioorg Med Chem Lett 2003;13:3597-3600 (Pubitemid 37141437)
78. Schering-Plough Corp. Piperidine derivatives useful as CCR3 antagonists. US20050182095; 2005
79. Ting PC, Lee JF, Wu J, et al. The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists. Bioorg Med Chem Lett 2005;15:1375-1378 (Pubitemid 40268995)
80. Ting PC, Umland SP, Aslanian R, et al. The synthesis of substituted bipiperidine amide compounds as CCR3 ligands: antagonists versus agonists. Bioorg Med Chem Lett 2005;15:3020-3023 (Pubitemid 40755189)
81. Teijin Limited. Piperidine derivatives having CCR3 antagonism. WO2003087089; 2003
82. Teijin Limited. 4,4-Disubstituted piperidine derivatives having CCR3 antagonism. WO2003091245; 2003
83. Mitsubishi Pharma Corp. N-oxide compounds. WO2004037817; 2004
84. Mitsubishi Pharma Corp. Morpholine compound. WO2006028284; 2006
85. Mitsubishi Pharma Corp. Salt of morpholine compound. WO2008007691; 2008
86. AstraZeneca AB. N-Benzyl-morpholine derivatives as modulators of the chemokine receptor. WO2007011292; 2007
87. Novartis AG. Piperazine derivatives with CCR3 inhibiting activity. WO2006015851; 2006
88. Boehringer Ingelheim Pharma GmbH & Co. 1-Phenyl-1,2-diaminoethane derivatives as modulators of the chemokine receptor activity. US2004063779; 2004
89. Novartis AG. Organic compounds. WO2005075420; 2005
90. Bristol-Myers Squibb Co. Substituted fused bicyclic amines as modulators of chemokine receptor activity. WO2005079497; 2005
91. Novartis AG. 1, 3-Disubstituted azetidine derivatives for use as CCR-3 receptor antagonists in the treatment of inflammatory and allergic diseases. WO2005026113; 2005
92. Novartis AG. Organic compounds. WO2006015854; 2006
93. Novartis AG. Organic compounds. WO2006015852; 2006
94. Novartis AG. Arylurea derivatives as modulators of chemokine receptor activity WO2007048771; 2007
95. Sanofi-Aventis. Amino-alkyl-amide derivatives as CCR3 receptor ligands. WO2007034251; 2007
96. Sanofi-Aventis. Amino-alkyl-amide derivatives as CCR3 receptor liquids. WO2007034252; 2007
97. Sanofi-Aventis. Amino-alkyl-amide derivatives as CCR3 receptor ligands. WO2007034253; 2007
98. Sanofi-Aventis. Amino-alkyl-amide derivatives as CCR3 receptor ligands. WO2007034254; 2007
99. Pegurier C, Collart P, Danhaive P, et al. Pyrrozolone methylamino piperidine derivatives as novel CCR3 antagonists. Bioorg Med Chem Lett 2007;17:4228-4231 (Pubitemid 47021396)
100. Kowa Company, Ltd. Tetrahydroisoquinoline compound. WO2008123582; 2008
101. Novartis AG. Use of fused imidazole derivatives to mediate CCR3 related conditions. WO2007025751; 2007
102. Bayer Healthcare AG. 2-Phenoxy-and 2-phenylsulfomamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders. WO2004084898; 2004
103. Boehringer Ingelheim Pharma Gmbh & Co. Pyrrolidinohydrochinazolines. WO2004072074; 2004
104. Anderskewitz R, Bauer R, Bodenback G, et al. Pyrrolidinohydroquinazolines-a novel class of CCR3 modulators. Bioorg Med Chem Lett 2005;15:669-673 (Pubitemid 40143144)
105. Gauvreau GM, Boulet LP, Cockroft DW, et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am Respir Crit Care Med 2008;177:952-958
106. Hodgson S, Charlton S, Warne P. Chemokines and drug discovery. Drug New Perspect 2004;15:335-338
107. Peterson D, Ognjenovic M. American chemistry society-228th National meeting: inflammation. IDrugs 2004;7:904-906
108. Hansel T. Study protocol for GW766994: a double blind randomized two way crossover placebo-controlled study in 12 subjects with seasonal allergic rhinitis to investigate the degree of inhibition afforded by GW766994 against eotazin-induced eosinophilia in nasal and skin tissues. Available from: http://www.rbht.nhs.uk/research/projects/?entryid31 = 46250&q = 0%c2%acGW766994%c2%ac [last accessed 23 February 2009]
109. Perks B. Synthetic chemists catch their breath. Chem World 2004;1(8)
110. Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000;105:651-665
111. Humbles AA, Lloyd CM, McMillan SJ, et al. A critical role for eosinophils in allergic airways remodeling. Science 2004;305:1776-1779 (Pubitemid 39249645)
112. Blyth DI, Wharton TF, Pedrick MS, et al. Airway subepithelial fibrosis in a murine model of atopic asthma. Am J Respir Cell Mol Biol 2000;23:241-246
113. Flood-Page P, Menzies-Gow AN, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029-1036 (Pubitemid 38056318)
114. Sanderson CJ. Interleukin-5, eosinophils and disease. Blood 1992;79:3101-3109
115. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176:1062-1071 (Pubitemid 350223751)
116. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199-204
117. O'Byrne PM. The demise of anti-IL-5 for asthma, or not. Am J Respir Crit Care Med 2007;176:1059-1061
118. Bochner B. Verdict in the case of therapies versus eosinophils: the jury is still out. J Allergy Clin Immunol 2004;113:3-9 (Pubitemid 38096156)
119. O'Byrbe OM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol 2001;108:503-508 (Pubitemid 32978017)
120. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003;167:1655-1659
121. Liu LY, Sedgwick JB, Bates ME, et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increase soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol 2002;169:6452-6458
122. Liu LY, Sedgwick JB, Bates ME, et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J Immunol 2002;169:6459-6466
123. Gregory B, Kirchem A, Phipps S, et al. Differential regulation of human eosinophil IL-3, IL-5 and GS-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression. J Immunol 2003;170:5359-5366 (Pubitemid 36617820)
124. IL-5R Ph II trial announced by MedImmune on news-medical.net. Available from: http://www.news-medical.net/?id = 43864 [Last accessed 19 February 2009]
125. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-984
126. Nair P, Pizzichini MMM, Kjarsgaard M, et al. Mepolizumab for predisonedependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-993
127. Pease JE, Horuk R. Chemokine receptor antagonists: Part 1. Expert Opin Ther Patents 2009;19:39-58 • An up to date reference on biology targeting CC chemokine receptors and on chemistry of CC chemokine receptor antagonists.
128. Murdoch RD. The Challenges of drug discovery & development, an oral presentation, 4th James Black Conference. University of Hertfordshire, 2006